Liraglutide Peptide

Liraglutide Peptide is a human glucagon like peptide-1 (GLP-1) receptor agonist. It consists of 31 amino acids and is a linear polypeptide, unique in that a C16 fatty acid side chain is connected to the 26th lysine. This structural modification endows Lilalutide with many excellent properties, making it play an important role in the treatment of diabetes and weight management. There are two key changes compared to natural GLP-1 molecules. One is that the 34th lysine of the natural GLP-1 molecule is replaced by arginine, and the other is that a glutamic acid mediated 16 carbon palmitoyl fatty acid side chain is added to the 26th lysine. This unique molecular change brings multiple advantages.

​

Liraglutide COA

Liraglutide Peptide, as a long-acting GLP-1 receptor agonist, is currently approved globally and in China as a core hypoglycemic drug with dual indications for blood glucose control and cardiovascular protection. In type 2 diabetes patients with atherosclerotic cardiovascular disease (ASCVD, including coronary heart disease, myocardial infarction, ischemic stroke, peripheral artery disease), heart failure, hypertension, and dyslipidemia, it has multiple clinical values of "reducing blood sugar, weight, heart, and kidney".

 

Diagnosis of atherosclerotic cardiovascular disease
Coronary heart disease: history of old myocardial infarction, unstable angina, stable angina, and coronary artery revascularization (PCI/CABG).
Cerebrovascular disease: ischemic stroke, transient ischemic attack (TIA), asymptomatic cerebral infarction.
Peripheral vascular disease: Lower limb arterial occlusive disease, carotid artery stenosis ≥ 50%.

 

Combined heart failure
Heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), NYHA grades II-IV.
Multiple cardiovascular high-risk factors
Age ≥ 55 years old+hypertension+dyslipidemia+smoking+obesity (BMI ≥ 27 kg/m ²), any two or more of them.

 

Non applicable population (contraindications/caution)
Type 1 diabetes, diabetes ketoacidosis; Personal/family history of medullary thyroid cancer (MTC) and multiple endocrine neoplasia type 2 (MEN-2).
History of recurrence of acute pancreatitis and chronic pancreatitis; Severe liver and kidney dysfunction (eGFR<15 ml/min/1.73m ²) should be used with caution.

Reference information source:

1. Novo Nordisk China. Liraglutide Injection (Novolytek) NMPA Cardiovascular Indications Approval Announcement 2020-05-14.
2. Chinese biopharmaceuticals. Beilin ® Instructions for Liraglutide Injection (3ml: 18mg). 2025
3. DailyMed. Victoza (liraglutide) FDA Label. 2026.
4. Endocrinology Branch of Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2024) Chinese Journal of Endocrinology and Metabolism, 2024
5. LEADER Research Collaboration Group. Liraglutide cardiovascular outcome study protocol and population baseline characteristics two thousand and sixteen

 

Anti atherosclerosis mechanism

Improving endothelial function: Activating GLP-1R in endothelial cells, promoting nitric oxide (NO) synthesis, dilating blood vessels, and improving endothelial dependent vasodilation function (EDV) by 30% to 40%. Inhibit endothelial cell apoptosis, reduce endothelial damage markers (endothelial microbubbles, sICAM-1), and reduce the risk of atherosclerosis initiation.

Inhibit plaque progression and stabilize vulnerable plaques: reduce vascular smooth muscle cell proliferation and migration, inhibit plaque volume growth (animal experiments inhibit 7.8%). Reduce macrophage infiltration, inflammatory factors (TNF - α, IL-6, hs CRP), and tissue protease activity within plaques, increase collagen content, and lower the risk of plaque rupture.
Regulating lipid metabolism: reducing triglycerides (-15%~-20%), small and dense LDL-C (-10%~-15%), mildly increasing HDL-C (+5%~+8%), and reducing lipid deposition.

Mechanisms of myocardial protection and anti heart failure

 

Improving myocardial energy metabolism: increasing the ratio of creatine phosphate to ATP in the myocardium, enhancing myocardial contraction reserve, improving myocardial perfusion, and increasing the 6-minute walking distance by 33m.
Inhibition of myocardial remodeling and fibrosis: inhibits proliferation of myocardial fibroblasts, reduces collagen deposition, lowers left ventricular mass index, and improves left ventricular diastolic function.
Reduce myocardial ischemia-reperfusion injury: activate the PI3K/Akt pathway, reduce ischemic myocardial cell apoptosis, and shrink myocardial infarction area (animal experiment -28%).

Lowering blood pressure, reducing weight, and optimizing metabolism
Hypotensive effect: Systolic blood pressure decreases by 3-5 mmHg, diastolic blood pressure decreases by 2-3 mmHg, independent of weight loss and reducing vascular burden.
Powerful weight loss: an average weight loss of 4.3kg (LEADER) and a waist circumference of 8.2cm, reducing abdominal obesity and cardiac burden.
Anti inflammatory and antioxidant: reduce hs CRP, IL-6, oxidative stress markers (MDA, ROS), and alleviate chronic inflammation throughout the body.
Renal synergistic protection
Reduce the urinary albumin/creatinine ratio (UACR -25% to -40%), delay eGFR decline, and lower the risk of kidney disease progression and cardiovascular death.

Reference information source:

1. PMC. Liraglutide cardiovascular protection mechanism. Circ Res. 2021.
2. European Journal of Cardiology GLP-1RA has independent anti atherosclerosis and anti-inflammatory effects two thousand and twenty-six
3. PubMed. Liraglutide improves myocardial perfusion and energy metabolism in T2DM. 2025.
4. LEADER Study Group. Liraglutide and cardiovascular outcomes. N Engl J Med. 2016.
5. Chinese Society of Cardiology Chinese expert consensus on GLP-1 receptor agonists for cardiovascular protection two thousand and twenty-five

 

Combined coronary heart disease (most applicable population)

Applicable scenarios: 30 days after acute coronary syndrome (ACS), stable coronary heart disease, PCI/CABG surgery, and recurrent angina pectoris.
Core benefit: Reduced risk of recurrent myocardial infarction and cardiovascular death (HR=0.82). Improve myocardial ischemia, reduce the frequency of angina attacks, and enhance exercise tolerance. Lowering blood sugar without increasing hypoglycemia, without causing heart failure, and without inducing stent thrombosis.
Usage: Starting at 0.6mg qd for 1 week → maintaining at 1.2-1.8mg qd, without the need to adjust dosage due to coronary heart disease.

Combined ischemic stroke/TIA

 

Applicable scenarios
Previous ischemic stroke TIA, Asymptomatic carotid artery stenosis (≥ 50%).
Core benefits (confirmed by Chinese research)
The recurrence rate of stroke was 7.9% vs 13.8%, with a risk reduction of 44% (HR=0.56).
Improve 90 day neurological outcomes and reduce disability rates.
Reduce the risk of post-stroke depression and cognitive decline.

Combined heart failure (HFrEF/HFpEF)

 

Applicable scenarios
NYHA grades II-IV, LVEF ≤ 40% (HFrEF) or LVEF ≥ 50% (HFpEF).
Core benefits
Reduce the risk of worsening heart failure hospitalization by 18% to 27%.
Improve 6-minute walking distance and alleviate exertional breathing difficulties.
No heavy water and sodium retention, no negative muscle force effect.
attention
Severe heart failure (NYHA IV) requires monitoring of volume; Used in conjunction with SGLT-2i as a golden combination.

Reference information source:

1. Chinese Medical Association Cardiovascular Disease Branch. Expert consensus on diagnosis and treatment of diabetes combined with coronary heart disease (2025) Chinese Journal of Cardiovascular Disease, 2025
2. JAMA Neurol. Liraglutide reduces recurrent stroke in T2DM with AIS/TIA. 2025.
3. PubMed. Liraglutide in heart failure: meta-analysis of RCTs. 2025.
4. Chinese Journal of New Drugs. The application of liraglutide in various subtypes of ASCVD two thousand and twenty-five
5. Novo Nordisk Guidelines for clinical application of Victoza combined with cardiovascular disease two thousand and twenty-four

Combined with SGLT-2 inhibitors

 

Protocol: Liraglutide 1.8mg qd+Dapagliflozin 10mg qd/Engrelizin 10mg qd.
Collaborative benefits
The risk of MACE is reduced by 25% to 30%, cardiovascular mortality is reduced by 30%, and hospitalization for heart failure is reduced by 40%.
Double kidney protection, effective weight loss (-8~-12kg), and extremely low risk of hypoglycemia.
Applicable: All patients with type 2 diabetes combined with ASCVD/heart failure are the first choice.

Combined with Metformin

Plan: Liraglutide+Metformin (1000-2000mg/d).
Benefits: An additional decrease of 1.0% to 1.5% in HbA1c, weight loss synergy, and combined cardiovascular protection.
Taboo: Metformin is contraindicated for renal insufficiency (eGFR<30).
Combination therapy with statins/antiplatelet agents

There is no drug interaction with atorvastatin, aspirin, or clopidogrel, and there is no increased risk of bleeding.
Can be safely used for ACS/stroke dual therapy period.
Avoid using combination drugs
When used in combination with a potent insulin secretagogue (glimepiride), the dosage should be reduced by 20% to 50% to avoid hypoglycemia.
Not used in combination with GLP-1RA weekly preparations (mechanism duplication).

Reference information source:

1. ADA/EASD. Consensus on Hyperglycemia Management of Type 2 diabetes (2025). Diabetes Care, 2025
2. Diabetes Branch of Chinese Medical Association Expert Consensus on Clinical Application of GLP-1RA (2025) Chinese Journal of diabetes, 2025
3. PubMed. Liraglutide + SGLT-2i in CVD: meta-analysis. 2025.
4. Chinese Medical Forum Newspaper. Combined hypoglycemic pathway in patients with cardiovascular disease and diabetes two thousand and twenty-six
5. Beilin ® Liraglutide injection. Drug interaction instructions two thousand and twenty-five

Hot Tags: liraglutide peptide, China liraglutide peptide manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, MT2 Injection, glp1 shot, etelcalcetide structure